Andy Weymann, MD, MBA – 25 Year Experience Leader is Appointed to VirtaMed BOD

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Andy Weymann, MD, MBA has more than 25 years of experience working in the medical device and biotech/pharma industry and as an orthopedic surgeon reports VirtaMed.

He has extensive experience developing and launching products and a track record leading international medical training initiatives. Prior to joining VirtaMed, Dr. Andy Weyman spent 13 years as chief medical officer and senior vice president at Smith+Nephew where he provided global leadership and oversight of the Scientific, Clinical and Medical Affairs organization, with accountability for market and business development.

Andy’s appointment brings a strong medical perspective to the VirtaMed board of directors, which already consists of four economic, business and technology leaders. As part of his role, Andy will help VirtaMed optimize and develop its product portfolio — to efficiently provide data-driven and needs-based simulation training to healthcare organizations. Andy will provide guidance and expertise throughout the product development process through to worldwide market implementation.

With Andy’s medical background as a practicing orthopedic surgeon specializing in trauma, sports medicine, and orthopedics, there are many synergies with VirtaMed’s leading arthroscopy simulators. His appointment is expected to bring valuable support and insight that will enable VirtaMed to develop more advanced therapeutic procedures.

Speaking about joining VirtaMed Andy stated, “As a surgeon and having led AO Education, training many surgeons around the globe, I understand how important hands-on experience in a real-world setting is. The unique data-platform of VirtaMed offers world-class virtual-reality simulation that bridges this gap and I strongly believe it has and will continue, to deliver unique value in surgical training and market development.”

Andy obtained his master’s degree in human medicine at the University of Zurich, Switzerland. He completed his MBA at the Simon Business School, University of Rochester, N.Y. More recently during the last year, he completed the ‘Making Corporate Boards More Effective’ program at the Harvard Business School in Boston.

VirtaMed CEO, Raimundo Sierra said, “The expansion of the VirtaMed board demonstrates our commitment to medical education, complementing our proven expertise in developing medical education tools with the latest technology. Andy has great insight into how VirtaMed can deliver value within the patient pathway and I look forward to him directing our efforts in this regard.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.